- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
7
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
7 companies
Camurus
Market Cap: SEK 37.8b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 617.50
7D
1.7%
1Y
-4.8%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 223.60
7D
0%
1Y
-20.8%
BioArctic
Market Cap: SEK 29.0b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 319.60
7D
1.7%
1Y
34.2%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.60
7D
-1.0%
1Y
-18.0%
Egetis Therapeutics
Market Cap: SEK 3.4b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 7.16
7D
1.1%
1Y
31.1%
AlzeCure Pharma
Market Cap: SEK 926.7m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.74
7D
-2.9%
1Y
41.9%
Moberg Pharma
Market Cap: SEK 514.2m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 11.08
7D
10.9%
1Y
29.6%